Rheumatoid arthritis: What is refractory disease and how to manage it?

Despite the enthusiastic progresses in the field of rheumatoid arthritis pharmacotherapy the presence of prognostic factors associated with an unfavorable outcome and the inappropriate and/or delayed initiation of DMARDs can diminish the likelihood of achieving remission and increase the probability of refractoriness to treatment.During the last decade we have experience exciting developments regarding the approval of new treatment options but few patients are reaching sustained remission and refractory patients continue to be a problem. Thus, it is critical to understand how clinicians can decrease the risk of refractoriness by close monitoring disease activity, using well defined and accepted composite measures, and by early and optimized use of DMARDs, including biologics.The goal of this review paper is to offer an evidence based roadmap to prevent and to deal with refractory RA.

► Refractory disease is defined as failure to attain a predefined target, which is now accepted to be remission or, at least, a low disease activity state.
► Despite the enthusiastic progresses in the field of rheumatoid arthritis pharmacotherapy, few patients are still reaching sustained remission.
► Refractoriness can be mitigated by tight monitoring and early use of both synthetic and biologic DMARDs aiming remission at each individual patient.